Antibody/Targeted-Drug Conjugates 2019

6-8 November 2019, Queen’s University Belfast, Belfast, Northern Ireland, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Provisional Conference Programme | Wednesday 6th November 2019

Registration

Welcome & Opening Remarks
ATDC 2019 Chairman Chris Scott
(The Queen’s University Belfast, Belfast, Northern Ireland, UK)

SESSION 1:
OPENING PLENARY SESSION

Moderator: Chris Scott
(The Queen’s University Belfast, Belfast, Northern Ireland, UK)

KEYNOTE
‘Site-specific conjugation in ADC design: Panacea or hype/ Lessons from a case study with a maytansinoid conjugate’

John Lambert
(Attager Consulting/The Queen’s University Belfast, Belfast, Northern Ireland, UK)

Coffee Break

SESSION 2:

Moderator: To be confirmed

‘Title to be confirmed’
Roger Beerli
(NBE Therapeutics Ltd, Basel, Switzerland)

‘Exploiting a drug discovery platform based on engineered VNAR domains for the development of novel protein drug conjugates targeting ROR1’
Graham Cotton
(ALMAC, Belfast, Northern Ireland, UK)

‘Enabling the targeted delivery of protein degraders using antibodies’
Thomas Pillow
(Genentech Inc., San Francisco, California, USA)

Moderator-led Session Discussion

Discussion, Questions & Answers

Lunch Break

SESSION 3:
CANCER

Moderator: Victor Goldmacher
(Forbius (Formation Biologics), Inc., USA)

‘Development of an EFGR targeted ADC for pancreatic cancer’
Michelle Green
(Queen’s University Belfast, Belfast, Northern Ireland, UK)

‘DR5 targeted nanosystems for the treatment of drug resistant pancreatic cancer’
Michael Johnston
(Queen’s University Belfast, Belfast, Northern Ireland, UK)

‘PMSA targeted drugs for prostate cancer’
Speaker to be confirmed

Moderator-led Session Discussion

Tea Break

SESSION 4:

Moderator: John Lambert
(Attager Consulting/The Queen’s University Belfast, Belfast, Northern Ireland, UK)

‘Title to be confirmed’
Steve Conlan
(University of Swansea, Swansea, Wales, UK)

‘Forming the “Invisible” Bridge: Optimisation and appraisal of pyridazinediones in antibody-drug conjugate synthesis’
Calise Bahou1,2, Elizabeth A. Love2, James R. Baker1 and Vijay Chudasama1,3
(1 Department of Chemistry, University College London, London; 2 LifeArc, SBC Open Innovation Campus, Stevenage, UK; 3 Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal)

‘Process development and manufacturing of Antibody-Drug conjugates’
Guy de Roo
(Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands)

Moderator-led Session Discussion

 

ATDC 2019 Delegates

Login details will be supplied after you have registered for the event.


ATDC 2019 Sponsors

  • ADC Review
  • Lonza
  • Sutro Biopharma
  • ONdrugDELIVERY
  • Genovis
  • NBE Therapeutics
  • Catalent Biologics
  • NatureGeneTherapy.com
  • ImmunoGen
  • OncoZine
  • Genentech
  • Aldevron
  • LinXis
  • Cancer Targeting Solutions Consulting
  • Almac Discovery

ATDC 2019 Downloads

ATDC 2019 Leaflet

ATDC 2019 Mailing List

Name
E-mail Address
What is 3+2-1?